Summary: Calcitonin gene-related peptide, originally found in rat medullary thyroid carcinoma cells, was measured by radioimmunpassay in plasma samples with added aprotinin from 17 normal volunteers and 21 patients with medullary thyroid carcinoma. The concentrations were below 75 pmol/1 in all 17 normal subjects with a mean of 33 ±19 pmol/1 plasma. In the patients, the plasma calcitonin gene-related peptide concentrations ranged from below 5 pmol/1 to 236 pmol/1, although the mean (36 ± 48 pmol/1) was not significantly different from the mean normal level. Increase in the plasma calcitonin gene-related peptide level was observed in 2 of 5 patients in response to infusion of 4.3 mg/kg of calcium for 10 minutes and in 3 of S patients in response to infusion öf 4 g/kg of tetragastrin for 5 minutes. These observations suggest that measurement of calcitonin gene-related peptide level may be helpful in determination of diseases in which the level of calcitonin is of less diagnostic value.
Introduction
calcitonin is mainly synthesized in the thyroid, and __ r . , , . t .
-" . . --1 . . calcitonin gene-related peptide mainly in the central With the Isolation of a cell stram with low calcitonin . 1 . . . , . .
. nervous System (3, 4) . synthesizmg capacity by repetitive metagenetic cultüre pf rat medullary thyroid carcinoma cells, it became Unlike many other known peptides, calcitonin genepossible to stüdy the mode of expressiön of the cal-related peptide was synthesized artificially by a procitonin gene; this cell strain was shown to synthesize cedure established on the basis of molecular analysis calcitonin gene-related peptide, which differs from of the calcitonin gene, and it was then detected in calcitonin (1) . It is now generally accepted that twö vivo by an immunohistological method. Calcitonin kinds of peptides are coded by the calcitonin gene, gene-related peptide reportedly exerts various physand that mRNA transcribed from the calcitonin gene iological actions, such äs suppression of appetite (5) , undergoes two alternative types of splicing to become inhibitipn of secretion of gastric acid or gastric juice calcitonin mRNA (which encodes calcitonin) or cal-(6, 7), vasodilatation (8) , Inhibition of gallbladder citonin gene-related peptide mRNA (which encodes contractility (9) , and Stimulation of secretions of renin calcitonin gene-related peptide) (2, 3) . This splicing (10) and atrial natriuretic peptide (11) . Immunohismechanism has been reported to be organ-^specific: tological studies have shown that calcitonin gene-related peptide is widely distributed in the central nervous System (4, 12, 13) and in peripheral ganglia (14) , suggesting that it may be an neurotransmitter. However, the physiological role(s) of this peptide in humans is unknown. We established a radioimmunoassay for the measurement of human calcitonin gene-related peptide and determined the plasma concentrations of this peptide in healthy subjects and patients with medullary thyroid carcinoma.
Materials and Methods

Materials
Human calcitonin gene-related peptide(l -37), rat calcitonin gene-related peptide(l -37), human calcitonin(l -32), and human parathyrin(l -84) were purchased from the Peptide Institute (Osaka, Japan (15) . Anti-rabbit-globulin goat serum. and normal rabbit serum were from Eiken Immunochemical Co. (Tokyo, Japan). All other materials were from Wako Pure Chemical Co. (Osaka, Japan).
Subjects
The subjects examined were 17 healthy volunteers (mean age ± SD, 31 ± 9 years: r nge, 20-49 years; 4 males and 13 females) and 21 patients with medullary thyroid carcinoma (41 ±13 years; 14-63 years; 4 males and 17 females). The diagnosis of medullary thyroid carcinoma was established by the presence of hypercalcitoninaemia either in the basal state or in response to calcium infusion in the test described below, and was confirmed surgically in all cases. Blood samples were obtained early in the morning after an overnight fast using syringes containing 4mmol/l EDTA · 2Na and 0.5 χ l O 6 KIU/1 of aprotinin. Samples were cooled on ice and promptly centrifuged, and the plasma was stored at -50 °C until used. Five of the medullary thyroid carcinoma patients (2 males, 3 females) received a provocation test with 4.3 mg/kg (iv, 10 minutes) of calcium (20 g/l calcium Chloride) or 4 μg/kg (iv, 5 minutes) of tetragastrin, and blood samples were taken before and after the test.
Radioimmunoassay of calcitonin gene-related peptide
Control plasma was prepared s follows: Normal human peripheral blood was collected in assay tubes containing 4 mmol/1 EDTA · 2 Na and 0.5 χ ΙΟ 6 KIU/1 of aprotinin, and plasma was separated by centrifugation for 10 minutes at 3000 g. This normal plasma was mixed with 50 g/kg charcoal (Norite A) with stirring for l hour and centrifuged at 10000g-for 30 minutes. The resulting supernatant was filtered twice through a millipore filter (type HA, pore size 0.45 μπι; Millipore Corporation, Massachusetts). The radioactivity of human J25 I-labelled calcitonin gene-related peptide remaining after this procedure was less than 1%. For assay of human calcitonin generelated peptide the reaction mixture, total volume 500 μΐ, contained 100 μΐ of control plasma (containing Standard human calcitonin gene-related peptide) or test plasma, about 20000 counts per minute of human 125 I-labelled calcitonin gene-related peptide, anti-calcitonin gene-related peptide serum diluted to a final concentration of 1:18000, an appropriate amount of aprotinin to give a final eoncentration of 2 χ ΙΌ 6 KIU/1, and buffer. The buffer employed was 100 mmol/1 sodram phosphate buffer containing 150 mmol/1 NaCl, 1.2 mmol/1 EDTA, and 15 mmol/1 NaN 3 (pH 7.4). After incubation of the mixture of 4 °C for 48 hours, bound and free human calcitonin gene-related peptide were separated by the double antibody method, with the second antibody and normal rabbit serum, with incubation at 4 °C for 24 hours. Some plasma samples were examined in an assay System without aprotinin.
Stability of human
125 I-labelled calcitonin gene-related peptide in plasma samples
The stability of human 125 I-labelled calcitonin gene-related peptide in plasma was studied s follows. Plasma samples from normal subjects after overnight fasting were collected in assay tubes containing 4 mmol/1 EDTA · 2 Na alone. Samples were incubated s described above and also for 96 hours instead of 48 hours. After incubation, the mixtures were subjected to gel chromatography on a Bio Gel P-2 column (1.6 χ 50 ein). Materials were eluted with the assay buffer, and their elution profiles were compared.
Radioimmunoassay for calcitonin
Plasma calcitonin was determined with a commercial radioimmunoassay kit (D iichi Radioisotope Laboratories, Ltd., Tokyo, Japan) by the procedure described previously (16) .
Statistical analysis
Statistical analyses were performed by Studenfs t test. Concentrations of plasma calcitonin gene-related peptide of less than the detection limit (5 pmol/1) were taken s 5 pmol/1.
Results
Stability of human
125 I-labelled calcitonin gene-related peptide I-labelled calcitonin gene-related peptide(l -37) incubated with plasma samples with and without 1000 KlU/tube aprotinin. Most of the radioactivity in samples incubated for 48 hours without aprotinin was eluted in the low molecular region, indicating that much of the tracer was degraded during the incubation. This degradation progressed during further incubation for up to 96 hours, but was markedly inhib* itedbylOOOKIU/tube(2 χ l O 6 KIU/1) of aprotinine. Therefore, this concentration of aprotinin was added in all subsequent assays.
Radioimmunoassay for human calcitonin gene-related peptide 
Plasma calcitonin gene-related peptide levels in normal subjects and patients with medullary thyroid carcinoma As shown in figure 3 , the basal plasma concentrations of calcitonin gene-related peptide in normal subjects ranged from below the detection limit (< 5pmol/l) to 75 pmol/1, with a mean of 33 ± 19 pmol/1. The basal calcitonin gene-related peptide concentrations in medullary thyroid carcinoma patients ranged from below the detection limit to 236 pmol/1, although the mean level in this group (35 ± 48 pmol/1) did not differ significantly from that in the normal group. Figure 4 shows the relation between the plasma calcitonin and calcitonin gene-related peptide levels in the 21 patients with medullary thyroid carcinoma. There was a significant correlation (r = 0.48, p < 0.05) between the two parameters after their logarithmic transformation. 5 pmol/1. The curve was not s tisfactory in the absence of aprotinin. The intra* and iriterassay coefficients of Variation were 6.0% and 8.0%, respectively, and the recovery was 104.9 ± 16.7%. When plasma samples containing three different concentfations of human calcitonin gene-related peptide were diluted sequentially, the res ltant dilution curve of each showed good linearity. The cr ss-reactivity of anti-rat Tyr°-calcitonin gene-related peptide(28-37) rabbit-serum with human calcitonin gene-related peptide(l -37) was 56% of its reactivity with rat calcitonin gener elated peptide(l-37). However, no cross-reactivity with either human calcitonin(l -32) or human parathyrin(l -84) was detected ( fig. 2) . 
Discussion
The anti-rat-Tyr° calcitonin gene-related peptide(28 -37) antibody used in this study was reported to crossreact with rat calcitonin gene-related peptide and human calcitonin gene-related peptide, but not with many other peptide hormones such äs human parathyrin, adrenocorticotropin, substance P, somatostatin and oxytocin (13) . In our experiment, the crossreactivity of human calcitonin gene-related peptide with this antibody was 56% of that of rat calcitonin gene-related peptide. Our assay System seems to be suitable for clinical use because a satisfactory Standard curve was obtained and good reproducibility of recovery was observed in dilution experiments.
Furthermore, the present study demonstrated that human 125 I-labelled calcitonin gene-related peptide was degraded appreciably in the plasma, and that this degradation was inhibited by aprotinin, an inhibitor of proteolytic enzymes. Kraenzlin et al. reported that calcitonin gene-related peptide was rapidly degraded in vivo, and that its half life in the circulatiön was less than 30 minutes (17) . These results süggest that plasma should be promptly separated and stored in an assay tube containing aprotinin, and that aprotinin should also be added before assays to prevent possible degradation of calcitonin gene-related peptide during incubation.
Recently, a method for measuring human calcitonin gene-related peptide by radioimmunoassay was reported by Zaidi et al. (18) . In their assay System, the detection limit was 5 pmol/1, and the crpss-reactivity of human calcitonin gene-related peptide with the antibody was 60% of that of rat calcitonin generelated peptide. They also used aprotinin for preventing degradation of the peptide. Thus our assay system was comparable with theirs.
By our assay, the mean circulating concentration of calcitonin gene-related peptide in normal subjeets was 33 ± 19 pmol/1, which was similar to the value reported by Girgis et al. (19) .
Calcitonin gene-related peptide was first discovered in a inolecular biological study of rat medullary thyroid carcinoma, and its level is thought to be elevated in patients with medullary thyroid carcinoma: in fact there are some reports of high levels of calcitonin gene-related peptide in these patients. An early report revealed rather high levels of circulating calcitonin gene-related peptide in patients with medullary thyroid carcinoma, but did not give details of the assay Systems, including whether aprotinin was used to prevent degradation of the tracer in the assay system (15). Mason et al. measured circulating calcitonin gene-related peptide after extraction of plasma by acid ethanol, and detected high levels of calcitonin generelated peptide of 14-4866 pmol/1 in 19 of 21 patients with medullary thyroid carcinoma, but plasma concentrations of below the detection limit (10 pmol/1) in the other two patients (20) . They also observed increases in the circulating level of calcitonin generelated peptide in response to calcium and/or gastrin infusion in 6 patients (20) . Schifter et äl. also detected high basal levels of calcitonin gene-related peptide in 26 of 35 patients with medullary thyroid carcinoma, using a radioimmunoassay system with aprotiniü. They observed significantly higher circulating levels of calcitonin than those of calcitonin gene-related peptide in these patients, but they also observed that the ratio of the two peptides varied from patient to patient and that only a small number of eells in tumoürs were stained by änti-cälcitonin geöe-related peptide antibody (21) . However, in our study, äl-though the basal level of calcitonin gene-related peptide was high in oüe medullary thyröid carcinoma patient, the mean level in medullary thyroid carcinoma patients was not significantly different ffom that of normal controls. Moreover, changes in calci-tonin gene-related peptide levels after provocation with calcium or gastrin, which is known to stimulate calcitonin in man, differed in different individuals and were only modest in our study, although Mason et al. observed rather high responses of circulating calcitonin gene-related peptide in most of their patients with medullary thyroid carcinoma in these provocation tests.
The reason for the differences in the mean basal levels of calcitonin gene-related peptide and in its responses in provocation tests in our study and the studies of Mason et al. and Schifter et al. is unknown. A possible explanation is that the patients examined were in different stages of disease. Our patients may have been in a rather earlier stage of disease, äs their circulating calcitonin levels ranges from 10 pmol/1 to 3.3 nmol/1 whereas those of most of the patients of Mason et al. and Schifter et al. were more than our highest level, and ranged up to more than 100 nmol/1. The medullary thyroid carcinoma patients reported by Mason et al. and Schifter et al. included those with the much higher levels of circulating calcitonin than those in our study. But a few of their patients had calcitonin levels that were about the same äs those in our study, and these patients had similar plasma calcitonin gene-related peptide levels to those of our patients. Schifter et al. reported that calcitonin generelated peptide values increased rapidly in the terminal phase of this disease, and Mason et al. also stated that in their study the two patients with the highest plasma calcitonin gene-related peptide levels had particularly aggressive tumours.
It is interesting that the plasma calcitonin and calcitonin gene-related peptide levels in our medullary thyroid carcinoma patients in the early stage of the disease showed a significant positive correlation, since similar correlations were observed in the medullary thyroid patients studied by Mason et al. and Schifter etal. More extensive studies are necessary on the secretion of calcitonin gene-related peptide and its behaviour in the circulation in both normal subjects and patients with medullary thyroid carcinoma.
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